THNR ETF (Amplify Weight Loss Drug & Treatment ETF) is managed by Amplify ETFs with $4.4M in net assets. THNR expense ratio is 0.59%, holding 22 positions across sectors including Health Care, Unknown, Financials. Inception date: 2024-05-21.

THNR performance shows a YTD return of 0.90%. The 1-year return is 15.21%. THNR dividend yield stands at 1.61%, paid annually.

THNR top holdings include Novo-Nordisk A/S-Spons Adr (14.5%), Eli Lilly & Co (12.4%), Regeneron Pharmaceuticals, Inc. (6.2%), Amgen Inc. (5.9%), Arrowhead Pharmaceuticals Inc (5.9%). View all THNR holdings, sector breakdown, or dividend history.

THNR can be compared against other funds using the overlap calculator or side-by-side comparison tool. THNR alternatives are available via the screener, along with tax-loss harvesting opportunities.